Katz J, Khatry S K, Thapa M D, Schein O D, Kimbrough Pradhan E, LeClerq S C, West K P
Johns Hopkins Bloomberg School of Public Health, Division of Disease Prevention and Control, Department of International Health, Room W5009, 615 N Wolfe Street, Baltimore, MD 21205-2103, USA.
Br J Ophthalmol. 2004 Dec;88(12):1487-92. doi: 10.1136/bjo.2004.044412.
To assess whether povidone-iodine provided any benefit over and above a standard regimen of antibiotic therapy for the treatment of corneal ulcers.
All patients diagnosed with corneal ulcers presenting for care at a primary eye care clinic in rural Nepal were randomised to a standard protocol of antibiotic therapy versus standard therapy plus 2.5% povidone-iodine every 2 hours for 2 weeks. The main outcomes were corrected visual acuity and presence, size, and position of corneal scarring in the affected eye at 2-4 months following treatment initiation.
358 patients were randomised and 81% were examined at follow up. The two groups were comparable before treatment. At follow up, 3.9% in the standard therapy and 6.9% in the povidone-iodine group had corrected visual acuity worse than 20/400 (relative risk (RR) 1.77, 95% confidence interval (CI) 0.62 to 5.03). 9.4% in the standard therapy and 13.1% in the povidone-iodine group had corrected visual acuity worse than 20/60 (RR 1.39, 95% CI 0.71 to 2.77), and 17.0% and 18.8% had scars in the visual axis in each of these groups, respectively (RR 1.11, 95% CI 0.67 to 1.82).
A small proportion of patients with corneal ulceration treated in this setting had poor visual outcomes. The addition of povidone-iodine to standard antibiotic therapy did not improve visual outcomes, although this design was unable to assess whether povidone-iodine on its own would have resulted in comparable visual outcomes to that of standard therapy.
评估聚维酮碘在治疗角膜溃疡方面,相对于标准抗生素治疗方案是否具有额外益处。
所有在尼泊尔农村一家初级眼科诊所就诊并被诊断为角膜溃疡的患者,被随机分为接受标准抗生素治疗方案组,以及接受标准治疗方案加每2小时使用2.5%聚维酮碘,持续2周的治疗组。主要结局指标为治疗开始后2至4个月时患眼的矫正视力,以及角膜瘢痕的存在情况、大小和位置。
358例患者被随机分组,81%的患者接受了随访。两组在治疗前具有可比性。随访时,标准治疗组中有3.9%的患者矫正视力低于20/400,聚维酮碘组中有6.9%的患者矫正视力低于20/400(相对危险度(RR)1.77,95%置信区间(CI)0.62至5.03)。标准治疗组中有9.4%的患者矫正视力低于20/60,聚维酮碘组中有13.1%的患者矫正视力低于20/60(RR 1.39,95%CI 0.71至2.77),且两组中分别有17.0%和18.8%的患者视轴出现瘢痕(RR 1.11,95%CI 0.67至1.82)。
在此环境下接受治疗的一小部分角膜溃疡患者视力预后较差。在标准抗生素治疗中添加聚维酮碘并未改善视力预后,尽管该设计无法评估单独使用聚维酮碘是否会产生与标准治疗相当的视力预后。